Deciphering Price-Earning (PE) Multiple as a Valuation Tool
A high quality asset can be a poor investment if acquired at an obscenely high valuation (versus its intrinsic value). On the other hand, even…
Blog
Decoding Maize Cycle & Potential Winners
Traditionally the maize crop in India had two large user industries – The remaining 10-15% would be consumed by humans as sweet corn, makki-ki-roti (corn…
Deciphering Promoter Buying & Selling – A Nuanced Take
I often ask this to the delegates in my Investing Workshop at FLAME Investment Lab, Pune, ‘Why did this specific guy win out of 456…
Talk at GIC | Mean Reversion Framework
Stalwart’s CIO, Jatin Khemani, recently gave a talk at Gurugram Investor Club where he presented on Stalwart’s Mean Reversion Framework with multiple case studies from…
Strategies work, Stocks don’t!
Value investing works, and so does growth investing. Quality investing works and so does chor-bane-mor (improving governance). Start-up investing works, and so do turnarounds. Even…
Shutting Down Treasure Trove
Stalwart Advisors has been running an independent equity research service called ‘Treasure Trove’ for over a decade now. Following are some stats covering this decadal…
Is Hold = Buy ? A Perennial Debate
Model Portfolio vs Customized Portfolio In the investing world, there are two schools of thought – one which believes there are only two states for…
Memo – Risk, Benchmarking & Taxation
Stalwart PMS completed its first full year of operation in May 2024, this memo is intended to help our initial partners understand our risk mitigation…
Exiting Suven Pharma with 663% Return in 4.5 years!
We invested in Suven Pharma in December 2019 (pre-demerger) at a price of Rs 131 a share (adjusted for the demerger of Suven Life Sciences). Over the last four…
Nifty@21,700: What should be the Portfolio Strategy for 2024?
‘Market has risen too much too soon, a crash can come anytime. I have started selling’ ‘I am raising 20% cash (i.e. selling 20% of…